• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scilex Holding Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/20/25 4:29:17 PM ET
    $SCLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCLX alert in real time by email
    8-K
    0001820190false00018201902025-03-192025-03-190001820190sclx:WarrantsToPurchaseOneShareOfCommonStockEachAtAnExercisePriceOf1150PerShareMember2025-03-192025-03-190001820190sclx:CommonStockParValue00001PerShare2Member2025-03-192025-03-19

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    _______________________

    FORM 8-K
    _______________________

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported): March 19, 2025

    _______________________

    SCILEX HOLDING COMPANY
    (Exact name of registrant as specified in its charter)

    _______________________

    Delaware
    (State or other jurisdiction
    of incorporation)

    001-39852
    (Commission
    File Number)

    92-1062542
    (IRS Employer
    Identification No.)

     

    960 San Antonio Road, Palo Alto, California, 94303
    (Address of principal executive offices, including zip code)

    (650) 516-4310

    Registrant’s telephone number, including area code

    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    _______________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

     

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

     

     

    ☐

     

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

     

     

    ☐

     

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

    (Title of each class)

    (Trading Symbol)

    (Name of exchange on which registered)

    Common Stock, par value $0.0001 per share

    SCLX

    The Nasdaq Stock Market LLC

    Warrants to purchase one share of common stock, each at an exercise price of $11.50

    SCLXW

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

     


     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On March 19, 2025, Scilex Holding Company (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, a total of (i) 29,057,097 shares of the Company’s Series A preferred stock, $00001 par value per share (the “Series A Preferred Stock”), or 100% of the 29,057,097 shares of Series A Preferred Stock, issued and outstanding, and (ii) 169,406,091 shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), or approximately 70% of the 243,312,885 shares of Common Stock, issued and outstanding as of the close of business on February 24, 2025, the record date for the Special Meeting, were represented virtually or by proxy.

     

    The holders of Series A Preferred Stock were entitled to vote, together with the holders of Common Stock and not separately as a class, on an as converted to Common Stock basis for an aggregate of 32,596,097 votes as a result of the adjustments to the deemed conversion price of such preferred stock in accordance with the Certificate of Designations of Series A Preferred Stock, filed with the Delaware Secretary of State on November 10, 2022.

     

    At the Special Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on February 27, 2025.

     

    Set forth below is a brief description of each proposal voted upon at the Special Meeting and the voting results with respect to each proposal.

     

    Proposal No. 1: To approve any amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock, within a range of 1-for-14 to 1-for-50 (or any number in between), without reducing the authorized number of shares of the Common Stock, and the filing of a final amendment with the ratio within such range to be determined in the sole discretion of the Board of Directors of the Company at any time on or before March 19, 2026, without further approval or authorization of the Company’s stockholders (the “Reverse Stock Split Proposal”).

     

    Votes For

    Votes Against

    Abstentions

    151,124,713

    49,235,399

    1,642,350

     

    Proposal No. 2: To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal.

     

    Votes For

    Votes Against

    Abstentions

    151,840,294

    47,342,114

    2,820,054

     

    An adjournment of the Special Meeting was not necessary because there were sufficient votes in favor of the Reverse Stock Split Proposal.

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

    104

    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

    2

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    SCILEX HOLDING COMPANY

     

     

     

     

    By:

    /s/ Jaisim Shah

     

    Name:

    Jaisim Shah

    Date: March 20, 2025

    Title:

    Chief Executive Officer and President

     

    3

     


    Get the next $SCLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCLX

    DatePrice TargetRatingAnalyst
    1/27/2025$22.00Buy
    D. Boral Capital
    10/16/2024$14.00Buy
    Alliance Global Partners
    6/13/2024$13.00Buy
    Rodman & Renshaw
    10/16/2023$4.00Buy
    B. Riley Securities
    10/13/2023$4.00Buy
    B. Riley Securities
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

      5/9/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

      PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicia

      5/1/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

      PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days.

      4/30/25 1:46:47 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Scilex Holding with a new price target

      D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

      1/27/25 8:08:33 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Scilex Holding with a new price target

      Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

      10/16/24 8:01:57 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

      Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

      6/13/24 7:16:15 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject

      4/22/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

      PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record

      3/10/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 3,250,000 shares, decreasing direct ownership by 6% to 51,039,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/23/25 7:49:49 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 779,371 shares, decreasing direct ownership by 1% to 54,289,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/17/25 8:27:54 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 5,000,000 shares, decreasing direct ownership by 8% to 55,068,585 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/6/25 7:12:44 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

      7/23/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

      PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

      3/4/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      4/25/24 5:25:28 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Scilex Holding Company (Amendment)

      SC 13D/A - Scilex Holding Co (0001820190) (Subject)

      3/5/24 4:22:28 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      12/18/24 7:04:41 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/31/24 12:44:57 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/29/24 6:59:31 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCLX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Scilex Holding Company

      SCHEDULE 13G/A - Scilex Holding Co (0001820190) (Subject)

      5/8/25 4:15:17 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:30:11 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:24:45 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care